After finishing at $50.56 in the prior trading day, Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed at $51.61, up 2.08%. In other words, the price has increased by $+1.05 from its previous closing price. On the day, 559765 shares were traded.
Ratios:
Our goal is to gain a better understanding of RARE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.49 and its Current Ratio is at 2.61. In the meantime, Its Debt-to-Equity ratio is 3.39 whereas as Long-Term Debt/Eq ratio is at 3.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 08, 2023, initiated with a Overweight rating and assigned the stock a target price of $72.
Evercore ISI Upgraded its In-line to Outperform on June 06, 2023, whereas the target price for the stock was revised from $60 to $80.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 11 ’24 when Kassberg Thomas Richard sold 11,509 shares for $49.93 per share. The transaction valued at 574,644 led to the insider holds 252,823 shares of the business.
Fust Matthew K sold 12,195 shares of RARE for $620,443 on Mar 07 ’24. The Director now owns 14,860 shares after completing the transaction at $50.88 per share. On Mar 01 ’24, another insider, Harris Erik, who serves as the EVP & Chief Commercial Officer of the company, sold 4,768 shares for $53.76 each. As a result, the insider received 256,328 and left with 67,163 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4.17B and an Enterprise Value of 3.63B. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.79 while its Price-to-Book (P/B) ratio in mrq is 15.43. Its current Enterprise Value per Revenue stands at 8.37 whereas that against EBITDA is -7.03.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $54.98, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is 47.91, while the 200-Day Moving Average is calculated to be 42.22.
Shares Statistics:
The stock has traded on average 731.43K shares per day over the past 3-months and 622.38k shares per day over the last 10 days, according to various share statistics. A total of 82.32M shares are outstanding, with a floating share count of 77.02M. Insiders hold about 6.45% of the company’s shares, while institutions hold 104.48% stake in the company. Shares short for RARE as of Mar 15, 2024 were 3.78M with a Short Ratio of 5.36, compared to 3.56M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.59% and a Short% of Float of 4.78%.
Earnings Estimates
Its stock is currently analyzed by 16 different market analysts. On average, analysts expect EPS of -$1.76 for the current quarter, with a high estimate of -$1.39 and a low estimate of -$2.04, while EPS last year was -$2.33. The consensus estimate for the next quarter is -$1.63, with high estimates of -$1.36 and low estimates of -$2.01.
Analysts are recommending an EPS of between -$5.23 and -$8.12 for the fiscal current year, implying an average EPS of -$6.44. EPS for the following year is -$4.96, with 18 analysts recommending between -$1.58 and -$6.82.
Revenue Estimates
14 analysts predict $116.17M in revenue for the current quarter. It ranges from a high estimate of $124.6M to a low estimate of $98.8M. As of the current estimate, Ultragenyx Pharmaceutical Inc.’s year-ago sales were $100.5M, an estimated increase of 15.60% from the year-ago figure. For the next quarter, 14 analysts are estimating revenue of $125.41M, an increase of 15.80% over than the figure of $15.60% in the same quarter last year. There is a high estimate of $130.1M for the next quarter, whereas the lowest estimate is $120.38M.
A total of 17 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $530.01M, while the lowest revenue estimate was $499.73M, resulting in an average revenue estimate of $513.15M. In the same quarter a year ago, actual revenue was $434.25M, up 18.20% from the average estimate. Based on 18 analysts’ estimates, the company’s revenue will be $645.82M in the next fiscal year. The high estimate is $920.7M and the low estimate is $541.73M. The average revenue growth estimate for next year is up 25.90% from the average revenue estimate for this year.
